Specify a stock or a cryptocurrency in the search bar to get a summary
Enlivex Therapeutics Ltd
1BTEnlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. Address: 14 Einstein Street, Ness Ziona, Israel, 7403618
Analytics
WallStreet Target Price
9.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 1BT
Dividend Analytics 1BT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 1BT
Stock Valuation 1BT
Financials 1BT
Results | 2019 | Dynamics |